We now confirmed that auxiliary assessment of ERCC1-transcripts considerably expanded the phenotypic spectrum of CTC-detection in pre- and post-therapeutic blood samples and that ERCC1 obviously marks a definable CTC-phenotype with overlap to the CTC-population, as detected by the AdnaTest Ovarian Cancer. This evidence concerns the gene ERCC1 and ovarian carcinoma.